BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
PRODID:-//Telerik Inc.//Sitefinity CMS 14.4//EN
BEGIN:VTIMEZONE
TZID:Central America Standard Time
BEGIN:STANDARD
DTSTART;VALUE=DATE:20250101
TZNAME:Central America Standard Time
TZOFFSETFROM:-0600
TZOFFSETTO:-0600
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DESCRIPTION:Speaker:\nLisa H. Lancaster\, MD&nbsp\;\nMedical Director\, Int
 erstitial Lung Disease Program&nbsp\;\nProfessor of Medicine&nbsp\;\nDivis
 ion of Allergy\, Pulmonary and Critical Care Medicine&nbsp\;\nVanderbilt U
 niversity Medical Center&nbsp\;\nNashville\, TN&nbsp\;\nLearning Objective
 s\nUpon completion of this activity\, participants should be able to:\n\n 
    Differentiate idiopathic pulmonary fibrosis (IPF) from other common ILD
 s\, such as connective tissue disease-associated ILD (CTD-ILD)\, accuratel
 y and efficiently using recommended clinical evaluation\, radiologic testi
 ng\, and pathologic testing as needed\n    Apply evidence informing the us
 e of antifibrotic therapy\, nonpharmacologic strategies\, and management o
 f risk factors and comorbidities in patients with IPF to formulate treatme
 nt plans\n    Individualize treatment of IPF based on patient characterist
 ics and preferences\, using shared decision-making\n\nRegister Today\nThis
  activity is provided by&nbsp\;Paradigm Medical Communications\, LLC.\nHel
 d in collaboration with the Pulmonary Fibrosis Foundation.
DTEND:20210622T164500Z
DTSTAMP:20260313T111708Z
DTSTART:20210622T154500Z
LOCATION:Virtual
SEQUENCE:0
SUMMARY:TEAM IPF:  Thorough Evaluation and Appropriate Management of Idiopa
 thic Pulmonary Fibrosis
UID:RFCALITEM639089794280998587
X-ALT-DESC;FMTTYPE=text/html:<p><strong>Speaker:</strong><br>\nLisa H. Lanc
 aster\, MD&nbsp\;<br>\nMedical Director\, Interstitial Lung Disease Progra
 m&nbsp\;<br>\nProfessor of Medicine&nbsp\;<br>\nDivision of Allergy\, Pulm
 onary and Critical Care Medicine&nbsp\;<br>\nVanderbilt University Medical
  Center&nbsp\;<br>\nNashville\, TN&nbsp\;</p>\n<p><strong>Learning Objecti
 ves</strong><br>\nUpon completion of this activity\, participants should b
 e able to:</p>\n<ul>\n    <li>Differentiate idiopathic pulmonary fibrosis 
 (IPF) from other common ILDs\, such as connective tissue disease-associate
 d ILD (CTD-ILD)\, accurately and efficiently using recommended clinical ev
 aluation\, radiologic testing\, and pathologic testing as needed</li>\n   
  <li>Apply evidence informing the use of antifibrotic therapy\, nonpharmac
 ologic strategies\, and management of risk factors and comorbidities in pa
 tients with IPF to formulate treatment plans</li>\n    <li>Individualize t
 reatment of IPF based on patient characteristics and preferences\, using s
 hared decision-making</li>\n</ul>\n<p style="text-align: center"><a href="
 https://ce.paradigmmc.com/a/34385P2d287G" target="_blank" class="button bu
 tton--outline">Register Today</a></p>\n<p>This activity is provided by&nbs
 p\;Paradigm Medical Communications\, LLC.<br>\nHeld in collaboration with 
 the Pulmonary Fibrosis Foundation.</p>
END:VEVENT
END:VCALENDAR